Clinical trial
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell…
NCT00084747 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00084747 |
|---|---|
| Title | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma |
| Official title | Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation With VELCADE Maintenance as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 30 |
| Start date | Jun 1, 2004 |
| Primary completion | Jan 1, 2013 |
| Completion | Jan 1, 2013 |
| First posted | Jun 11, 2004 |
| Last update posted | Aug 17, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: